山东
齐鲁网·闪电新闻5月14日讯抗癌药物“博优诺”历经10年研发、6个关键阶段，于2021年成功上市，已为全国20万癌症患者带来希望。从37℃恒温细胞培养、20天无菌扩增，到15-20项严苛的质量检测，再到蛋白纯化与色谱分析，每一步都凝聚着科技与匠心。见证山东“全域布局、多点开花”的生物医药产业崛起。创新制药，山东智造——为健康未来赋能！
The anti-cancer drug "Boyounuo" (Bevacizumab Injection), after 10 years of R&D and 6 critical phases, was launched in 2021, bringing hope to 200,000 cancer patients nationwide. From 37°C sterile cell culture and 20-day expansion to 15-20 rigorous quality tests, protein purification, and chromatographic analysis, every step embodies innovation and precision. It reflects Shandong’s "full-spectrum strategy with multi-point breakthroughs" in biomedicine. Innovative pharmaceuticals, intelligently crafted in Shandong—powering a healthier future!
翻译：高嘉慕（实习）
Translator: Qiu Wenxin (Intern)
闪电新闻记者 刘勇君 报道
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
